2020

Investor Materials

The safe secure way to view your investor
materials and to vote your proxy

Investor Materials


Mobirise

ANNUAL REPORT

2019
Mobirise

PROXY STATEMENT

2020

Online Voting.

VOTE Anywhere, Anytime!  Your vote is IMPORTANT! Vote your shares on your computer, tablet or mobile device. Vote by phone by dialing 866-249-5670.

Mobirise

ANNUAL MEETING

DATE

July 31, 2020

TIME 

1:30 PM PT

VIRTUAL MEETING

To Register for the Meeting



Deadline to Register*
July 29, 2020
5:00 PM ET  

*Note: You must register by the deadline to be eligible to participate in the meeting.

Mobirise

About Biocept

At Biocept, we are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy.

Our team of scientific experts has spent years working to change the way physicians look at blood in cancer patients. We have developed a unique, patented methodology to isolate rare cells—such as circulating tumor cells, (CTCs) as well as cell-free circulating tumor DNA (ctDNA) from the blood, allowing us to provide both analytically and clinically validated and exploratory biomarker analysis, all without a tissue sample.

Biocept’s services are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Our liquid biopsies have been used by doctors in thousands of patient cases. We partner with industry leaders and major cancer centers, continually advancing the field of cancer diagnostics